diff --git a/.gitignore b/.gitignore
index 0386601..febfc5a 100644
--- a/.gitignore
+++ b/.gitignore
@@ -1,9 +1,13 @@
 *
-!tex
-tex/*
-!tex/*.tex
-!tex/*.bib
-!tex/*.glo
+!thesis
+thesis/*
+!thesis/*.tex
+!thesis/*.bib
+!thesis/*.glo
+
+!abstract
+abstract/*
+!abstract/*.tex
 
 !figures
 figures/*
diff --git a/abstract/abstract.tex b/abstract/abstract.tex
new file mode 100644
index 0000000..0eb002b
--- /dev/null
+++ b/abstract/abstract.tex
@@ -0,0 +1,57 @@
+\documentclass{article}
+\usepackage[top=1in,left=1in,right=1in,bottom=1in]{geometry}
+\usepackage{setspace}
+
+\pagestyle{empty}
+
+\begin{document}
+
+\begin{center}
+  \LARGE{\textbf{Optimizing T Cell Manufacturing and Quality Using
+      Functionalized Degradable Microscaffolds}}
+
+  \Large
+
+  \bigskip
+
+  Nathan J. Dwarshuis
+
+  \bigskip
+
+  165 pages
+  
+  \bigskip
+
+  Directed by Krishnendu Roy
+\end{center}
+
+\large
+
+\doublespacing{}
+
+Adoptive cell therapy using chimeric antigen receptor (CAR) T cells have shown
+promise in treating cancer, but manufacturing large numbers of high quality
+cells remains challenging. Currently approved T cell expansion technologies
+involve anti-CD3 and anti-CD28 antibodies, usually mounted on magnetic beads.
+This method fails to recapitulate many key signals found \textit{in vivo} and is
+also heavily licensed by a few companies, limiting its long-term usefulness to
+manufactures and clinicians. Furthermore, highly potent, anti-tumor T cells are
+generally less-differentiated subtypes such as central memory and stem memory T
+cells. Despite this understanding, little has been done to optimize T cell
+expansion for generating these subtypes, including measurement and feedback
+control strategies that are necessary for any modern manufacturing process.
+
+The goal of this dissertation was to develop a microcarrier-based degradable
+microscaffold (DMS) T cell expansion system and determine
+biologically-meaningful critical quality attitudes and critical process
+parameters that could be used to optimize for highly-potent T cells. We
+developed and characterized the DMS system, including quality control steps. We
+also demonstrated the feasibility of expanding high-quality T cells. We used
+Design of Experiments methodology to optimize the DMS platform, and we developed
+a computational pipeline to identify and model the effects of measurable
+critical quality attributes and critical process parameters on the final
+product. Finally, we demonstrated the effectiveness of the DMS platform
+\textit{in vivo}. This thesis lays the groundwork for a novel T cell expansion
+method which can be utilized at scale for clinical trials and beyond.
+
+\end{document}
\ No newline at end of file
diff --git a/tex/references.bib b/thesis/references.bib
similarity index 100%
rename from tex/references.bib
rename to thesis/references.bib
diff --git a/tex/thesis.glo b/thesis/thesis.glo
similarity index 100%
rename from tex/thesis.glo
rename to thesis/thesis.glo
diff --git a/tex/thesis.tex b/thesis/thesis.tex
similarity index 100%
rename from tex/thesis.tex
rename to thesis/thesis.tex
index ac39ef3..6971b15 100644
--- a/tex/thesis.tex
+++ b/thesis/thesis.tex
@@ -1,6 +1,6 @@
 \documentclass{report}
-\usepackage[section]{placeins}
 \usepackage[top=1in,left=1.5in,right=1in,bottom=1in]{geometry}
+\usepackage[section]{placeins}
 \usepackage{siunitx}
 \usepackage{multicol}
 \setlength{\columnsep}{1cm}